ATE528015T1 - Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür - Google Patents
Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafürInfo
- Publication number
- ATE528015T1 ATE528015T1 AT03726007T AT03726007T ATE528015T1 AT E528015 T1 ATE528015 T1 AT E528015T1 AT 03726007 T AT03726007 T AT 03726007T AT 03726007 T AT03726007 T AT 03726007T AT E528015 T1 ATE528015 T1 AT E528015T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- mammal
- endothelial cells
- prolifering
- application
- Prior art date
Links
- 210000002889 endothelial cell Anatomy 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/090,183 US7094410B2 (en) | 2002-03-02 | 2002-03-02 | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| PCT/US2003/006256 WO2003073995A2 (en) | 2002-03-02 | 2003-02-28 | Dna vaccine against proliferating endothelial cells and methods of use thereof. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE528015T1 true ATE528015T1 (de) | 2011-10-15 |
Family
ID=27787599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726007T ATE528015T1 (de) | 2002-03-02 | 2003-02-28 | Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7094410B2 (de) |
| EP (1) | EP1487482B1 (de) |
| JP (1) | JP4598401B2 (de) |
| KR (1) | KR100979898B1 (de) |
| CN (1) | CN1293917C (de) |
| AT (1) | ATE528015T1 (de) |
| AU (1) | AU2003228229B2 (de) |
| BR (1) | BRPI0308103B8 (de) |
| CA (1) | CA2477406C (de) |
| CY (1) | CY1112663T1 (de) |
| DK (1) | DK1487482T3 (de) |
| ES (1) | ES2371870T3 (de) |
| MX (1) | MXPA04008468A (de) |
| PL (1) | PL213364B1 (de) |
| PT (1) | PT1487482E (de) |
| RU (1) | RU2318019C2 (de) |
| SI (1) | SI1487482T1 (de) |
| WO (1) | WO2003073995A2 (de) |
| ZA (1) | ZA200406988B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1595548A3 (de) * | 2001-03-07 | 2006-02-22 | Mannkind Corporation | Anti-Neovaskulatur Präparationen zur Krebsbehandlung |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| KR100614220B1 (ko) | 2004-11-08 | 2006-08-21 | 고려대학교 산학협력단 | Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물 |
| CN101766818B (zh) * | 2008-12-30 | 2013-05-22 | 陕西北美基因股份有限公司 | 多糖金磁复合微粒载药体及其制备方法 |
| JP5539411B2 (ja) * | 2009-03-04 | 2014-07-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 血管新生因子を含む組成物およびその使用方法 |
| US9492523B2 (en) | 2011-12-09 | 2016-11-15 | The Board Of Regents For Oklahoma State University | Broadly protective Shigella vaccine based on type III secretion apparatus proteins |
| ES2650269T3 (es) * | 2011-12-22 | 2018-01-17 | Vaximm Ag | Método para producir cepas atenuadas de salmonela de alto rendimiento |
| CN104519908B (zh) | 2012-07-05 | 2020-10-30 | 万科斯蒙股份有限公司 | 用于胰腺癌患者的dna疫苗 |
| WO2014034735A1 (ja) | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Ｖｅｇｆ及び／又はアンギオポエチン－２の特異的エピトープを含むｄｎａワクチン |
| US10548962B2 (en) | 2012-10-22 | 2020-02-04 | The Board Of Regents For Oklahoma State University | Use of the salmonella SPP type III secretion proteins as a protective vaccination |
| US9950053B2 (en) | 2012-10-22 | 2018-04-24 | The Board Of Regents For Oklahoma State University | Use of the Salmonella SPP type III secretion proteins as a protective vaccination |
| US20180153976A1 (en) | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
| JP6947649B2 (ja) | 2015-06-18 | 2021-10-13 | バクシム アクチェンゲゼルシャフト | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン |
| RU2759227C2 (ru) * | 2020-04-10 | 2021-11-11 | Генетик Диагностикс Энд Терапи 21 Лтд | ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US6228844B1 (en) * | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| US5939400A (en) * | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| CA2310252A1 (en) * | 1998-03-06 | 1999-09-10 | Imclone Systems Incorporated | Active immunization against angiogenesis-associated antigens |
| WO2000014244A2 (en) * | 1998-09-04 | 2000-03-16 | Connaught Laboratories Limited | Treatment of cervical cancer |
| AU2001271976A1 (en) * | 2000-07-07 | 2002-01-21 | Corixa Corporation | Microspheres and adjuvants for dna vaccine delivery |
| US7094410B2 (en) * | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
-
2002
- 2002-03-02 US US10/090,183 patent/US7094410B2/en not_active Expired - Lifetime
-
2003
- 2003-02-28 EP EP03726007A patent/EP1487482B1/de not_active Expired - Lifetime
- 2003-02-28 PL PL372314A patent/PL213364B1/pl unknown
- 2003-02-28 MX MXPA04008468A patent/MXPA04008468A/es active IP Right Grant
- 2003-02-28 KR KR1020047013668A patent/KR100979898B1/ko active IP Right Grant
- 2003-02-28 RU RU2004129332/13A patent/RU2318019C2/ru active
- 2003-02-28 SI SI200332080T patent/SI1487482T1/sl unknown
- 2003-02-28 PT PT03726007T patent/PT1487482E/pt unknown
- 2003-02-28 CA CA2477406A patent/CA2477406C/en not_active Expired - Lifetime
- 2003-02-28 BR BRPI0308103A patent/BRPI0308103B8/pt not_active IP Right Cessation
- 2003-02-28 CN CNB038099470A patent/CN1293917C/zh not_active Expired - Lifetime
- 2003-02-28 DK DK03726007.2T patent/DK1487482T3/da active
- 2003-02-28 WO PCT/US2003/006256 patent/WO2003073995A2/en active Application Filing
- 2003-02-28 JP JP2003572517A patent/JP4598401B2/ja not_active Expired - Lifetime
- 2003-02-28 AU AU2003228229A patent/AU2003228229B2/en not_active Expired
- 2003-02-28 ES ES03726007T patent/ES2371870T3/es not_active Expired - Lifetime
- 2003-02-28 AT AT03726007T patent/ATE528015T1/de active
-
2004
- 2004-09-01 ZA ZA2004/06988A patent/ZA200406988B/en unknown
-
2006
- 2006-08-21 US US11/507,298 patent/US8048428B2/en active Active
-
2011
- 2011-10-25 US US13/280,855 patent/US8241637B2/en not_active Expired - Lifetime
- 2011-12-20 CY CY20111101264T patent/CY1112663T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE528015T1 (de) | Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür | |
| NZ613809A (en) | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies | |
| AU2003209259A8 (en) | Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof | |
| IS6750A (is) | Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka | |
| DK1448229T3 (da) | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr | |
| WO2003061591A3 (en) | Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis | |
| EA201270625A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| ATE454901T1 (de) | Verfahren zur erhaltung zellimmuneantworten gegen proteinen | |
| IL171966A0 (en) | Prostate stem cell antigen variants and pharmaceutical compositions based thereon | |
| ATE514433T1 (de) | Nucleotid und zelluläre vakzine-zusammensetzung | |
| DK1210411T3 (da) | Sammensætninger og fremgangsmåder til forbedret celledyrkning | |
| ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
| EA200601905A1 (ru) | Микрокапсулы с замедленным высвобождением, основанные на сополимере лактида и гликолида, включающие полипептид и сахар | |
| IL173078A0 (en) | Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form | |
| SE9800836D0 (sv) | New Compounds | |
| NO20055209L (no) | Peptabody for cancerbehandling | |
| WO2007149518A3 (en) | Dna composition against tumor stromal antigen fap and methods of use thereof | |
| WO2005077048A3 (en) | Immune modulation by regulating expression of the “minor” gene in immune dendritic cells | |
| ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
| WO2002088328A8 (en) | Method for generating highly active human dendritic cells from monocytes | |
| WO2004012681A3 (en) | Cancer vaccines containing epitopes of oncofetal antigen | |
| WO2002010350A1 (fr) | Technique de proliferation de cellules tueuses naturelles | |
| NO20083609L (no) | Fremgangsmater og sammensetninger for malrettet-RELT | |
| BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
| DE60238044D1 (de) | Tumortherapie mit vektoren auf sindbis virus-basis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1487482 Country of ref document: EP |